Patient organisation sustainability

CCDR work at the interface between patients, patient organisations, pharmaceutical companies, governments, clinicians and researchers. This portfolio of work focuses on supporting patient organisations as an essential part of the health system.

Six-country comparative assessment of government funding mechanisms supporting patient organisations and community-based health services.

Country-specific health economic benchmarks and models for potential cost savings, released organisational capacity, capability improvements and return on investment with shared services.

Consistent method for translating PEEK patient experience evidence into COA and outcome-measurement strategy globally, while adapting the resulting evidence plan to the regulatory, clinical-trial and HTA expectations. United States, United Kingdom, Australia, Canada, European Union, Germany, France,
Switzerland and Japan markets.

Comparative guide to the regulatory environments affecting collaboration between pharmaceutical companies and patient organisations across 26 countries.

This multi-stakeholder project identified a series of questions that patients can be asked in the context of HTA engagement

This project identifies the ways in which patients and patient organisations would like to participate in clinical trials.

An audit of patient organisation activities demonstrating their role as part of the health system, using the Australian context as a case study.

The patient organisation program of work has been supported by sponsorships and grants since 2013 from BeOne Medicines, Astra Zeneca, Novartis, Roche, Sanofi, Alexion, Ipsen, GSK, Gilead, Pfizer, AbbVie and MSD. CCDR thanks all funders for their support.